Systematic Reviews
Copyright ©The Author(s) 2023.
World J Crit Care Med. Mar 9, 2023; 12(2): 71-88
Published online Mar 9, 2023. doi: 10.5492/wjccm.v12.i2.71
Table 1 Studies showing efficacy of different devices for cytokine and endotoxin removal
Ref.Study typePopulationModalityInterventionOutcomes
Tapia et al[28], 2012Prospective cohort study31 severe septic shock patientsHVHF, Cytokine removalHVHF – single short term – 6 h at 40 mL/kg/h25/31 responded to HVHF. Decrease in NE dose and improvement in hemodynamic, metabolic and respiratory parameters were significantly improved by 4 h
Joannes-Boyau et al[29], 2013Prospective, randomized, open multicentre trial137 septic shock patients (AKI < 24 h)HVHF, Cytokine removalHVHF – 70 mL/kg/h vs standard volume hemofiltration at 35 mL/kg/h No difference in hemodynamic stability, severity scores, 28-d mortality, length of stay and vasopressor free days
Livigni et al[30], 2014Prospective, randomized, multicentre parallel group trial192 septic shock patientsCPFA, Cytokine & endotoxin removalConventional therapy (n = 93) vs CPFA (n = 91)Decreased mortality in patients receiving high dose of CPFA. No difference in length of ICU stay and new organ failures in 30 d
Atan et al[31], 2018Randomized controlled trial76 critically ill patients with AKICVVH -HCOCytokine removalCVVH-HCO (n = 38) – cut off point 100 kDa vs CVVH -Std (n = 38) – cut off point 30 kDaNo difference was observed in mortality, duration of hemofiltration, norepinephrine dose, serum albumin levels and filter life
Dellinger et al[32], 2018Randomized, multicentre trial449 septic shock patientsPolymyxin B hemoperfusion; Endotoxin removalPolymyxin B hemoperfusion + Standard therapy vs Sham hemoperfusion + Standard therapyNo significant difference in 28 d mortality in overall population or in patients with MODS score of > 9
Kaçar et al[33], 2020Prospective observational study23 septic shock patients with AKIHA 330 Cytokine removalHA 330 hemoperfusion + CVVH for 2 h once daily for 3 dIncrease in pH was observed after 1st application HA330 hemoperfusion; CRP and PCT levels decreased significantly after 2nd application